Skip to main content

Advertisement

Table 4 Number of patients (and percentage of subgroup total) in the Safety and Efficacy (ITT and PP) analysis populations, grouped by treatment duration

From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

  Treatment duration (months)  
Population < 4 4 > 4 Total
Safety 3 (9.4%) 14 (43.8%) 15 (46.9%) 32
Intent-to-treat (ITT) n.a. 14 (48.3%) 15 (51.7%) 29
Per-protocol (PP) n.a. 14 (56.0%) 11 (44.0%) 25
  1. n.a. = not applicable as this analysis population, by definition, contained no patients treated for less than 4 months